Published in J Manag Care Pharm on September 01, 2011
Chronic hepatitis C virus (HCV) disease burden and cost in the United States. Hepatology (2013) 2.62
Cost-effectiveness and budget impact of hepatitis C virus treatment with sofosbuvir and ledipasvir in the United States. Ann Intern Med (2015) 2.07
The cost-effectiveness of sofosbuvir-based regimens for treatment of hepatitis C virus genotype 2 or 3 infection. Ann Intern Med (2015) 1.89
Cost-effectiveness of Early Treatment of Hepatitis C Virus Genotype 1 by Stage of Liver Fibrosis in a US Treatment-Naive Population. JAMA Intern Med (2016) 1.77
Burden of disease and cost of chronic hepatitis C infection in Canada. Can J Gastroenterol Hepatol (2014) 1.59
Resource utilization and survival among Medicare patients with advanced liver disease. Dig Dis Sci (2014) 1.40
The new paradigm of hepatitis C therapy: integration of oral therapies into best practices. J Viral Hepat (2013) 1.37
The hepatitis C cascade of care: identifying priorities to improve clinical outcomes. PLoS One (2014) 1.25
Costs of telaprevir-based triple therapy for hepatitis C: $189,000 per sustained virological response. Hepatology (2014) 1.05
Cost-effectiveness of boceprevir in patients previously treated for chronic hepatitis C genotype 1 infection in the United States. Value Health (2013) 1.01
Achieving sustained virologic response in hepatitis C: a systematic review of the clinical, economic and quality of life benefits. BMC Infect Dis (2015) 0.94
Boceprevir for previously untreated patients with chronic hepatitis C Genotype 1 infection: a US-based cost-effectiveness modeling study. BMC Infect Dis (2013) 0.93
Hepatitis C virus therapy is associated with lower health care costs not only in noncirrhotic patients but also in patients with end-stage liver disease. Aliment Pharmacol Ther (2013) 0.92
Healthcare Costs for Chronic Hepatitis C in South Korea from 2009 to 2013: An Analysis of the National Health Insurance Claims' Data. Gut Liver (2017) 0.88
The cost-effectiveness of improved hepatitis C virus therapies in HIV/hepatitis C virus coinfected patients. AIDS (2014) 0.87
Current practices of screening for incident hepatitis C virus (HCV) infection among HIV-infected, HCV-uninfected individuals in primary care. Clin Infect Dis (2014) 0.86
Cost-effectiveness of Telaprevir combination therapy for chronic hepatitis C. PLoS One (2014) 0.84
Disease progression and health care resource consumption in patients affected by hepatitis C virus in real practice setting. Clinicoecon Outcomes Res (2016) 0.83
Prevalence of cirrhosis in hepatitis C patients in the Chronic Hepatitis Cohort Study (CHeCS): a retrospective and prospective observational study. Am J Gastroenterol (2015) 0.83
The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective. BMC Health Serv Res (2012) 0.80
Ascertainment and verification of end-stage renal disease and end-stage liver disease in the north american AIDS cohort collaboration on research and design. AIDS Res Treat (2015) 0.80
Economic and Public Health Impacts of Policies Restricting Access to Hepatitis C Treatment for Medicaid Patients. Value Health (2016) 0.80
Assessment of cost of innovation versus the value of health gains associated with treatment of chronic hepatitis C in the United States: The quality-adjusted cost of care. Medicine (Baltimore) (2016) 0.77
Outcomes and management of viral hepatitis and human immunodeficiency virus co-infection in liver transplantation. World J Gastroenterol (2014) 0.76
Pricey pills for an even pricier problem. Cancer (2015) 0.75
The Potential Return on Public Investment in Detecting Adverse Drug Effects. Med Care (2017) 0.75
Factors associated with success of telaprevir- and boceprevir-based triple therapy for hepatitis C virus infection. World J Hepatol (2017) 0.75
Hepatitis C in the era of direct-acting antivirals: real-world costs of untreated chronic hepatitis C; a cross-sectional study. BMC Infect Dis (2015) 0.75
Economic burden of hepatitis B infection among patients with diabetes. Hum Vaccin Immunother (2016) 0.75
Long-term disease and economic outcomes of prior authorization criteria for Hepatitis C treatment in Pennsylvania Medicaid. Healthc (Amst) (2016) 0.75
Efficacy and safety of BG-12 (dimethyl fumarate) and other disease-modifying therapies for the treatment of relapsing-remitting multiple sclerosis: a systematic review and mixed treatment comparison. Curr Med Res Opin (2013) 2.18
Hemorrhagic and thrombotic events associated with generic substitution of warfarin in patients with atrial fibrillation: a retrospective analysis. Ann Pharmacother (2011) 1.61
Public health and economic impact of the 13-valent pneumococcal conjugate vaccine (PCV13) in the United States. Vaccine (2010) 1.23
All-cause and bleeding-related health care costs in warfarin-treated patients with atrial fibrillation. J Manag Care Pharm (2011) 1.15
Evaluating Diagnosis and Treatment Patterns of COPD in Primary Care. Treat Respir Med (2006) 1.13
The economic impact of GERD and PUD: examination of direct and indirect costs using a large integrated employer claims database. Curr Med Res Opin (2005) 1.03
Antiplatelet medication management in patients hospitalized with ischemic stroke. Am J Health Syst Pharm (2007) 1.03
Clinical risk factors for fracture in postmenopausal osteoporotic women: a review of the recent literature. Ann Pharmacother (2008) 1.01
Comparison of current US risk strategy to screen for hepatitis C virus with a hypothetical targeted birth cohort strategy. Am J Public Health (2012) 0.93
Development of a practical screening tool to predict low muscle mass using NHANES 1999-2004. J Cachexia Sarcopenia Muscle (2013) 0.90
Assessing adherence-based quality measures in epilepsy. Int J Qual Health Care (2012) 0.89
Adherence and persistence with single-dosage form extended-release niacin/lovastatin compared with statins alone or in combination with extended-release niacin. Ann Pharmacother (2006) 0.89
Adherence with multiple-combination antihypertensive pharmacotherapies in a US managed care database. Clin Ther (2008) 0.89
Comparison of daily insulin dose and other antidiabetic medications usage for type 2 diabetes patients treated with an analog basal insulin. Curr Med Res Opin (2010) 0.87
Fat Modulates the Relationship between Sarcopenia and Physical Function in Nonobese Older Adults. Curr Gerontol Geriatr Res (2012) 0.86
Incidence and economic implications of heparin-induced thrombocytopenia in medical patients receiving prophylaxis for venous thromboembolism. Pharmacotherapy (2006) 0.85
Impact of adherence and weight loss on glycemic control in patients with type 2 diabetes: cohort analyses of integrated medical record, pharmacy claims, and patient-reported data. J Manag Care Spec Pharm (2014) 0.85
Gastrointestinal complications of over-the-counter nonsteroidal antiinflammatory drugs. J Pain Palliat Care Pharmacother (2006) 0.85
New therapies for treating Down syndrome require quality of life measurement. Am J Med Genet A (2013) 0.84
A benefit-risk analysis of natalizumab in the treatment of patients with multiple sclerosis when considering the risk of progressive multifocal leukoencephalopathy. Curr Med Res Opin (2013) 0.84
Public health and economic impact of vaccination with 7-valent pneumococcal vaccine (PCV7) in the context of the annual influenza epidemic and a severe influenza pandemic. BMC Infect Dis (2010) 0.83
The economic burden of advanced liver disease among patients with hepatitis C virus: a large state Medicaid perspective. BMC Health Serv Res (2012) 0.80
Clinical risk factors for fracture among postmenopausal patients at risk for fracture: a historical cohort study using electronic medical record data. J Bone Miner Metab (2010) 0.80
Physician adherence to ACR gout treatment guidelines: perception versus practice. Postgrad Med (2014) 0.79
Has the cost-effectiveness of Xolair (omalizumab) been underestimated? J Allergy Clin Immunol (2005) 0.78
Cost effectiveness of pharmacotherapy for the prevention of migraine: a Markov model application. CNS Drugs (2010) 0.78
Clinical, humanistic, and economic outcomes of gout. Am J Manag Care (2005) 0.78
Concurrent control of blood glucose, body mass, and blood pressure in patients with type 2 diabetes: an analysis of data from electronic medical records. Clin Ther (2011) 0.78
Use of clomiphene citrate in the University of Utah Community Clinics. J Reprod Med (2013) 0.78
Predictors of metabolic parameter monitoring in adolescents on antipsychotics in a primary care setting. Ment Health Fam Med (2012) 0.77
A review of recommended antibiotic therapies with impact on outcomes in acute otitis media and acute bacterial sinusitis. Am J Manag Care (2006) 0.77
Impact of body mass index on the incidence of cardiometabolic risk factors in ambulatory care settings over 5 years or more. Value Health (2009) 0.77
Metabolic monitoring of patients prescribed second-generation antipsychotics. J Psychiatr Pract (2013) 0.77
A cost-utility analysis of pregabalin versus duloxetine for the treatment of painful diabetic neuropathy. J Pain Palliat Care Pharmacother (2012) 0.77
Application of decision-analytic models in personalized medicine for CML treatment decisions made by payers, providers, and patients. J Manag Care Pharm (2012) 0.76
Cost effectiveness of liposomal doxorubicin vs. paclitaxel for the treatment of advanced AIDS-Kaposi's sarcoma. J Med Econ (2013) 0.75
Modeling the impact of the 13-valent pneumococcal conjugate vaccine serotype catch-up program using United States claims data. BMC Infect Dis (2012) 0.75
Contemporary management of patients with Type 2 diabetes. Expert Rev Cardiovasc Ther (2010) 0.75
Author's response to letter to the editor. Curr Med Res Opin (2014) 0.75
Association between second-generation antipsychotics and changes in body mass index in adolescents. J Adolesc Health (2013) 0.75
Back pain and productivity: measuring worker productivity from an employer's perspective. J Pain Palliat Care Pharmacother (2004) 0.75
Physician utilization by insurance type among youth with type 2 diabetes. Am J Manag Care (2010) 0.75
Management of epilepsy in adults. Treatment guidelines. Postgrad Med (2005) 0.75
Decision analysis: a primer and application to pain-related studies. J Pain Palliat Care Pharmacother (2008) 0.75
Management of epilepsy in adults. Diagnosis guidelines. Postgrad Med (2005) 0.75
Rethinking the total cost of care in AOM and ABS: The impact of improved diagnostic accuracy and antibiotic treatment where high efficacy and adherence are achievable. Am J Manag Care (2006) 0.75
Methodological challenges of comparative effectiveness research in pain: implications for investigators, clinicians, and policy makers. J Pain Palliat Care Pharmacother (2011) 0.75
Would depression management relieve pain and improve function. J Pain Palliat Care Pharmacother (2004) 0.75
Contraceptive and noncontraceptive benefits of the LNG-IUS in a vertically integrated HMO. Contraception (2008) 0.75